We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

GnRH Agonist and Intrauterine Insemination

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00503217
Recruitment Status : Completed
First Posted : July 18, 2007
Last Update Posted : September 7, 2016
Information provided by (Responsible Party):

Study Description
Brief Summary:
The aim of this study is to assess whether GnRH agonist administration in the luteal phase improves pregnancy outcome in intrauterine insemination (IUI) cycles.

Condition or disease Intervention/treatment Phase
Intrauterine Insemination Drug: Tryptorelin Phase 4

Study Design

Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single
Official Title: Effect of GnRH Agonist Administration at the Time of Implantation in Intrauterine Insemination Cycles: A Randomized Controlled Trial
Study Start Date : February 2005
Primary Completion Date : December 2007
Study Completion Date : December 2007

Resource links provided by the National Library of Medicine

Drug Information available for: Deslorelin
U.S. FDA Resources

Arms and Interventions

Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 38 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Women < 38 years old
  • Bilateral tubal patency confirmed by hysterosonography
  • Normal ultrasound scan of uterus and ovaries
  • Normal day 3 basal hormones
  • Motile sperm count after capacitation ≥ 3 mill/ml

Exclusion Criteria:

  • Endometriosis
  • Polycystic ovary syndrome
  • Uterine disease (polyps, myomas and müllerian diseases)
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00503217

Instituto Valenciano de Infertilidad Spain
Valencia, Spain, 46015
Sponsors and Collaborators
Instituto Valenciano de Infertilidad, IVI VALENCIA
Principal Investigator: Jose Bellver, MD Instituto Valenciano de la Infertilidad
Principal Investigator: Elena Labarta, MD Instituto Valenciano de Infertilidad
More Information

Responsible Party: Jose Bellver, Gynecologist IVI Valencia, Instituto Valenciano de Infertilidad, IVI VALENCIA
ClinicalTrials.gov Identifier: NCT00503217     History of Changes
Other Study ID Numbers: VLC-JB-0205-307-9
First Posted: July 18, 2007    Key Record Dates
Last Update Posted: September 7, 2016
Last Verified: September 2016

Keywords provided by Jose Bellver, Instituto Valenciano de Infertilidad, IVI VALENCIA:
intrauterine insemination
GnRH agonist

Additional relevant MeSH terms:
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action